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Background
It has been proposed that the goal of treatment for osteoporosis should be an acceptably low risk of fracture and that treatment decisions should be guided by maximizing the probability that a patient will achieve the goal. (1, 2) The American Society for Bone and Mineral Research (ASBMR) and the United States National Osteoporosis Foundation (NOF) established the Working Group on 'Goal-directed Treatment for Osteoporosis' to consider setting goals to guide therapeutic decisions. The Working Group members were selected for their expertise and clinical experience in the management of osteoporosis. They represent a broad array of primary care and specialist clinicians and experts in epidemiology and ethics from the United States, Canada, Europe, Australia/New Zealand, and Japan.
Many are also members or leaders of other societies that focus on osteoporosis. The Working Group includes no representatives and received no funding from the pharmaceutical industry. Some members of the Working Group have received funds from pharmaceutical companies as described in the disclosures.
After several discussions of draft principles, the Working Group concluded that setting treatment goals with patients and making therapeutic decisions based on the likelihood of achieving those goals is an ideal strategy for treatment of osteoporosis. Some parts of this approach can be recommended for use in clinical practice now. Other components have limitations that need to be addressed before implementation in clinical practice. In particular, there is a need for new treatments that have more potent effects on fracture risk and bone mineral density (BMD) that would enable patients to achieve goals that may not be reachable with current therapies. Ideally, additional agents that act to maintain treatment targets (beyond intermittent bisphosphonates) are also needed to optimize the goal-directed treatment paradigm.
There is limited evidence on which to base principles of goal-directed treatment. This report describes principles based on interpretation of evidence that reflects a consensus of expert opinion of
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Differences between standard treatment and goal-directed treatment
With current guidelines for managing osteoporosis, once a decision has been made to treat a patient with a pharmacologic agent, a "first line" drug, usually an oral bisphosphonate, is prescribed. BMD is often repeated 1-2 years later to evaluate for response to therapy. Stabilization or improvement of BMD is usually accepted as validation that the patient is responding appropriately to treatment. The same treatment is then continued; after 3-5 years of oral or intravenous bisphosphonate therapy, a bisphosphonate "holiday" may be considered.(3) If there is a statistically significant decline in BMD 1-2 years after starting therapy, clinicians may evaluate for factors contributing to a suboptimal response to therapy and consider switching to a different agent. Sometimes bone turnover markers are used to monitor response to therapy, with a significant change in the expected direction (decreased with antiresorptive agents, increased with osteoanabolic agents) taken as an acceptable response.
In contrast, goal-directed treatment is a strategy where (a) a goal of treatment is established for a patient, (b) the initial choice of treatment is based on the probability of reaching the goal, and (c) progress toward reaching the patient's goal is reassessed periodically, with decisions to stop, continue, or change treatment based on achievement of the goal or progress toward achievement of the goal.
Goal-directed treatment differs from standard practice in a fundamental way. As with all treatment, the overriding goal of treatment is to achieve freedom from fracture or at least a low risk of fracture. If a fracture, including a morphometric vertebral fracture, occurs during treatment, despite evidence of response to treatment by improvement in BMD and markers of bone turnover, then the patient has an increased risk of a recurrent fracture for at least several years (4-6), warranting consideration of
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Principles of Goal-directed treatment
Establishing treatment goals
The principles of goal-directed treatment are founded on the identification of a target BMD or fracture risk to guide decisions about initial treatment and treatment decisions during the course of therapy. Currently, the NOF suggests initiating treatment in patients with hip or vertebral fractures, patients with a T-score in the lumbar spine, total hip or femoral neck ≤ -2.5, and those with a 10-year probability of hip fracture ≥ 3% or 10-year probability of major osteoporotic fracture ≥ 20%, using the US-adapted World Health Organization (WHO) absolute fracture risk model (FRAX ® ). (7) Osteoporosis treatment goals parallel indications for initiating treatment; logical treatment goals are BMD levels above and fracture risk levels below those for which treatment is usually recommended. In a patient with an incident fracture while on osteoporosis medication, treatment should be continued regardless of the T-score, since the risk of another fracture in the next few years is very high.(4-6) Once a fracture-free interval of 3-5 years has been documented, other treatment targets can be considered, as follows.
T-score as a goal. If the primary reason for starting treatment is a T-score ≤ -2.5 at the femoral neck, total hip, or lumbar spine by dual-energy X-ray absorptiometry (DXA), then the goal of treatment is a T-score > -2.5 at that skeletal site. Although absolute BMD (in g/cm 2 ) is used for quantitative comparison of serial BMD measurements by DXA, T-score is preferred as a goal because T-scores mitigate much of the BMD variability associated with different skeletal sites, regions of interest, and
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There is limited evidence that, for an individual patient, greater increases in BMD are associated with greater reductions in fracture risk. Previous meta-analyses (8) with a 95% level of confidence.(4) Therefore, reaching a T-score > -2.0 on a single measurement provides a very high degree of confidence that the T-score is truly > -2.5. Confidence that the goal Tscore > -2.5 has been achieved is also enhanced when the T-score at a skeletal site is > -2.5 on more than one measurement. In consideration of technical differences with DXA systems of different manufacturers and sources of measurement variability, measurements should ideally be made on the same device at the same facility, using the same reference databases to calculate T-scores, provided there is adherence to well-established quality standards (19) Despite its logical appeal as a treatment goal, fracture risk is currently not feasible for clinical practice.
Better methods for assessing fracture risk for patients on treatment are needed in order to enable use of fracture risk goals to guide therapeutic decisions.
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Goal-directed selection of initial therapy
The Working Group recognizes that selection of treatment is often based on, or constrained by, local policies and payer reimbursement practices. Furthermore, selection of therapy must consider patient age, stage of life, comorbidities, concomitant medications, falling risk and frailty, in addition to severity of osteoporosis.
For patients with recent fractures, it is critical to prevent fractures during the next several years, when the risk of another fracture is substantially elevated.(24-31) Therapeutic agents that reduce fracture risk rapidly are desirable for these patients.
For patients with a T-score substantially below -2.5, treatments having the potential to achieve a greater increase in BMD should be considered. The acceptable probability of achieving the treatment goal and the time to achieve it has not been established. Defining this probability requires analyses of the costs and benefits of alternative approaches. In the absence of such evidence, the Working Group judged that it was intuitively reasonable to expect that initial treatment should offer at least a 50% chance of achieving the treatment goal within 3 to 5 years of starting therapy. This level of probability has not been generated from trials of approved drugs and should be revised if evidence suggests that an alternative probability is more appropriate.
If initial treatment with an oral bisphosphonate offers a low probability of reaching the target Tscore of > -2.5, then an agent with substantially greater effect on BMD, if available, should be considered for initial therapy. Similarly, if initial treatment with an oral bisphosphonate offers a low probability that the patient will reach a goal of reduction in fracture risk, an agent or sequence or combination of agents with greater effect on fracture risk should be considered for initial therapy.
Choice of initial therapy should also consider the balance of expected benefits and potential risks, patient preference, and cost. This approach is feasible to apply to clinical practice currently.
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Goal-directed assessments and treatment decisions during treatment
Assessing adherence to treatment. Achieving a goal requires adherence to treatment. In general, taking less than 80% of prescribed oral medications is associated with a suboptimal therapeutic effect, which may be recognized by a decline in BMD, failure of bone turnover markers to respond as expected, or occurrence of a fracture. Poor adherence should prompt interventions to improve adherence.(32) The Working Group suggests that when adherence to an oral agent is inadequate, parenteral therapy should be considered. Levels of adherence with pill taking may be difficult to estimate in practice but can be approximated from electronic pharmacy records, if available, using the history of patient refills of prescribed therapy. Comparisons of adherence with oral and injectable therapy showed that treatment with SC denosumab every 6 months (33) and IV ibandronate every 3 months (34) produced better adherence than did weekly oral bisphosphonate.
Monitoring response to therapy.
A treatment goal cannot be achieved unless the patient is responding to therapy, although response to therapy is not a guarantee that the goal will be reached. A fracture occurring while on therapy warrants further evaluation to confirm no hidden underlying secondary causes of osteoporosis. Patients who have had fractures on treatment should not be considered to have achieved treatment goals until they have remained free of fracture for at least 3-5 years past the fracture. Guidelines recommend repeating a DXA study 1 to 2 years after starting therapy, and/or measuring a bone turnover marker (7, 35) to assure that there is a treatment response.
However, a patient may be a good responder with improvement in BMD or an appropriate change in bone turnover marker, yet still have an unacceptably high level of fracture risk. This could be because BMD remains very low, the patient had a recent fracture or there are underlying comorbidities or medications that increase fracture risk substantially. With the goal-directed approach, despite a treatment response being confirmed, consideration should be given to modifying therapy to help achieve treatment goals.
Patients whose BMD does not improve on treatment cannot achieve a T-score goal. Loss of BMD during treatment warrants evaluation of adherence and other causes of inadequate response to treatment. (7, 19, 35) Treatment monitoring should also include assessment of possible adverse effects of therapy, interval fracture history, assessment of back pain, and body height measurement to determine whether VFA should be repeated. (36) There have been no analyses of the best frequency for reassessing fracture history, re-screening
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This article is protected by copyright. All rights reserved 13 for vertebral fractures, or measuring height. Furthermore, the ideal interval for assessing BMD has not been studied and would depend on the difference between the patient's T-score and T-score goal and expected effects of the treatment. However, the Working Group judged that, in general, it would be reasonable to reassess patients yearly for assessment of adherence, interval medical history and height measurement, and at least every 2 to 3 years to determine whether the goal has been achieved or if there is a high likelihood that it will be achieved soon. Timely achievement of the treatment goal is desirable, although there is no analysis indicating an acceptable duration of treatment to achieve the goal. It is rational to utilize the medication most likely to achieve the BMD goal quickly in patients at highest risk for fracture.
Assessment of treated patients should include several elements: 
Limitations of goal-directed treatment
Although several principles of goal-directed therapy could be applied to clinical practice, the concept has limitations. (48) In particular, it may not be feasible for patients with a very high risk of fracture or very low BMD to achieve goals with current treatments; more potent treatments are needed. For example, with current treatments it may not be possible for a patient with a very high baseline risk of
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with the most potent agents should be considered. Optimal treatment sequences, such as anabolic therapy followed by a potent antiresorptive drug, could potentially achieve BMD goals (even in patients who start with very low BMD). This highlights the importance of selecting the most appropriate initial therapy in patients who are far below the ultimate T-score goal.
A goal of T-score > -2. 
Research needs
The evidence supporting some of the recommendations is limited. The choice of treatments should ideally be based on randomized trials that compare alternative strategies. Further study is needed to fully validate the clinical application of all aspects of goal-directed treatment (Table) . In particular, evidence and analyses are needed to determine levels of risk or T-score that warrant selection of more potent agents instead of a first-line bisphosphonate. We encourage those who sponsor trials of therapeutic agents to conduct comparative studies and analyses that would be valuable to defining goals of treatment and support choices of initial and follow-up treatment to reach those goals.
The Working Group recommends that studies be done to compare the probability of reaching a T-score goal with alternative treatments based on a patient's BMD and other characteristics; these could be done with existing data from clinical trials. It would be ideal to have trials that compare the anti-fracture efficacy of first-line therapies, such as alendronate, to more potent drugs in patients who have low probability of reaching a T-score goal. Fracture risk data are needed on the probability of achieving T-score goals based on the patient's starting T-score and other characteristics. These estimates should be generated from previous trials of current treatments in a form that is easy for clinicians to use.
As noted, the evidence for the potential benefit of switching treatment is limited to a few small short-term trials. (4, (39) (40) (41) (42) (43) (44) The Working Group recommends that trials be conducted comparing continuing bisphosphonate therapy versus switching to presumably more potent treatments for patients who have not reached a goal, or who continue to have high fracture risk. These trials should continue for at least 3 years to provide data about the probability that switching treatment will achieve a T-score goal with longer therapy. Ideally trials comparing continuing or switching treatment would have sufficient power to determine whether switching reduces the risk of fracture.
Models to estimate risk of fracture in patients who are receiving treatment are needed; these could be developed from existing data from clinical trials of approved drug treatments. In addition,
analyses of associations between change in BMD and change in risk of fracture during treatment are needed across all trials for vertebral, nonvertebral, and hip fractures and should be done for new treatments that have anti-fracture efficacy.
Patient's views about the value of setting goals would be valuable; further studies are needed to elucidate these. A recent study suggested that the threshold risk of fractures at which patients report they would be willing to take fracture prevention medication is quite variable.(53) Trials should compare the effect of setting goals to standard practice on patient's persistence and adherence with treatments.
Conclusions
This Working Group interim report supports the potential value of goal-directed treatment and sets out several principles to guide this approach to selecting and monitoring treatments. Some of these general principles, such as considering a more potent initial treatment in those with high risk of fracture, use of parenteral therapy for persistent non-adherence, measurement of height and vertebral imaging before and during treatment, and continuation or intensification of treatment when a vertebral fracture occurs on therapy, could be put into practice now. Others, such as estimating the probability of achieving goals with specific initial treatments, and deciding, based on risk, to continue or switch agents during treatment, lack evidence or assessment tools. These principles are based primarily on the judgment of experts who comprised the Working Group. Achievement of treatment goals presented here is not possible for all patients due to limited efficacy of medications that are currently available. This may change with the development and approval of new agents or combinations of medications that provide more robust effects on fracture risk and BMD than current agents. Finally, these preliminary principles should be revisited when relevant new data and analyses become available and when new treatments with substantially greater effects on BMD and fracture risk are approved.
